Call your healthcare provider for mild symptoms lasting more than 5-7 days, uncertainty about medication, blood sugar above 250 mg/dL (if diabetic), or new/worsening symptoms
Metformin: Co-administration of multiple twice-daily doses of metformin with sitagliptin did not meaningfully alter the pharmacokinetics of sitagliptin in patients with type 2 diabetes
Does Semaglutide Have Neuroprotective Benefits for MS Patients
For patients using semaglutide specifically for weight loss (those who are overweight or obese without diabetes), the risk increases even further, with a hazard ratio of 7.64, which is more than seven times greater than alternative medications
Dizziness and Fatigue : Anecdotal reports from human users document episodes of dizziness and fatigue following peptide administration
This article examines evolving health policies, coverage trends, and financial implications surrounding GLP1 medications, with a focus on their growing use for weight loss and other obesity-related comorbidities